Provided is a malleable implant configured to fit at or near a bone defect site to promote bone growth, the malleable implant comprising: a biodegradable polymer, mineral particles, and an oxysterol, the implant configured to become moldable upon being wetted with a fluid. Methods of making and use are further provided.

Provided is a compression resistant implant configured to fit at or near a bone defect to promote bone growth, the compression resistant implant comprising porous ceramic particles in a biodegradable polymer, and an oxysterol disposed in or on the compression resistant implant. Methods of making and use are further provided.

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. An implant is configured to fit inside of the middle meatus of a human nasal cavity. The implant includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate. The implant releases the mometasone furoate for more than 12 weeks. A second implant can also be provided configured to fit inside the middle meatus. The second implant also includes a therapeutic-agent formulation containing a layer of over 2000 micrograms of mometasone furoate, and releases the mometasone furoate for more than 12 weeks.

Aspects herein relate to coatings with crystallized active agent(s) and related methods. A method for coating a medical device herein includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device.

Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Embodiments herein include coatings with crystallized active agent(s) and related methods. In an embodiment, a method is included for coating a medical device including selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. In an embodiment, an elution control coating disposed on a medical device is included, the elution control coating including an active agent that is at least about 80% crystallized within one week of being disposed on the medical device. In an embodiment, a method is included for enhancing the formation of active agent crystals within a coating layer including adjusting the concentration of an active agent in a coating solution to reach some percentage of the active agent saturation point.

Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided.

The present invention relates to an artificial bile duct comprising ursodeoxycholic acid (UDCA), and due to comprising UDCA, the artificial bile duct of the present invention is effective in improving differentiation into cholangiocytes and preventing formation of bile stones.

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.